Advertisement

Advertisement
CNS Cancers
Skin Cancer

Drug Resistance in Melanoma-Related Leptomeningeal Disease

Researchers uncovered potential mechanisms driving drug resistance in patients with melanoma and leptomeningeal disease...

Lung Cancer

Dendritic Cell Therapy in Pleural Mesothelioma

As reported in The Lancet Oncology by Aerts et al, the phase II/III DENIM trial showed no overall survival benefit with a treatment comprising dendritic cells...

Solid Tumors
Genomics/Genetics

FDA Grants Accelerated Approval to Repotrectinib for NTRK Fusion–Positive Solid Tumors

On June 13, the U.S. Food and Drug Administration (FDA) granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients aged 12 years and...


Advertisement
Lung Cancer

Previously Treated Metastatic NSCLC: Sacituzumab Govitecan vs Docetaxel

As reported in the Journal of Clinical Oncology by Luis G. Paz-Ares, MD, PhD, and colleagues, the phase III EVOKE-01 trial has shown a numeric but not statistically...

Issues in Oncology

V. Craig Jordan, PhD, a Founding Father of Targeted Therapy in Cancer, Dies at Age 76

Craig Jordan, CMG, OBE, PhD, DSc, FMedSci, a pioneering scientist whose innovative work in breast cancer research has saved countless lives and will continue to impact...

Advertisement
Advertisement





More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Guideline Update Seeks to Aid Clinicians in the Selection of Systemic Treatments for Advanced Hepatocellular Carcinoma

An ASCO guideline update offers new recommendations on systemic treatment for advanced hepatocellular carcinoma (HCC), based on promising findings from several recent randomized controlled trials as well as the approval of new first- and second-line immunotherapy combinations.1 John D. Gordan, ...

Advertisement

Previously Treated Metastatic Colorectal Cancer: Lenvatinib/Pembrolizumab vs Standard of Care

As reported in the Journal of Clinical Oncology by Akihito Kawazoe, MD, and colleagues, the final analysis of  the phase III LEAP-017 trial showed no significant overall survival benefit with lenvatinib plus pembrolizumab vs the standard of care in previously treated patients with mismatch...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Palliative Care

In Celebration of a Remarkable Life and Career in Oncology

Jamie H. Von Roenn, MD, FASCO When Jamie H. Von Roenn, MD, FASCO, graduated from high school in 1970 and enrolled at the University of Illinois in Champaign, she was determined to seek a career in special education, because she wanted to “help people through difficult situations.” Although...

Issues in Oncology

FDA’s Oncology Center of Excellence Launches Project 5 in 5, a Crowdsourcing Initiative

OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team,...

Lenalidomide-Exposed Relapsed or Refractory Multiple Myeloma: BPd vs PVd

As reported at the 2024 ASCO Annual Meeting (Abstract LBA105) and in The New England Journal of Medicine by Meletios Dimopoulos, MD, and colleagues, an interim analysis from the phase III DREAMM-8 trial has shown significantly improved progression-free survival with belantamab mafodotin-blmf,...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Colorectal Cancer

I Am Living With Recurring Stage IV Colorectal Cancer

Despite urgings from my primary care physician to get a colonoscopy screening after I turned 50, I resisted. As a health-care provider, and someone who is tuned into changes in my body, I thought I would instinctively know if I had a serious illness. I was wrong. Even after finally relenting to at...

Advertisement

Advanced Neuroendocrine Tumors: Adding Lu-177 Dotatate to Standard First-Line Therapy

As reported in The Lancet by Simron Singh, MD, MPH, FRCPC, and colleagues, primary results of the international, multicenter, randomized phase III NETTER-2 study have shown significantly improved progression-free survival with the addition of the radioligand lutetium-177 dotatate (Lu-177 dotatate)...

ASCO Post X Feed
Social Media Hub by Everwall